More than a third of people who experienced psychosis with cannabis use later transitioned to schizophrenia, according to a systematic review and meta-analysis published online in Schizophrenia Bulletin.
A meta-analysis recently published in The Lancet Psychiatry found that using medicinal cannabinoids to treat mental health disorders cannot be justified, due to a lack of evidence of effectiveness and known risks of the substances.
People with schizophrenia with primary negative symptoms had significantly wider oral palates compared with patients with nondeficit schizophrenia as well as control subjects in a study published online in Schizophrenia Bulletin.
The US Food and Drug Administration (FDA) has approved a transdermal patch formulation of asenapine (Secuado) as the first patch for the treatment of adults with schizophrenia, Noven Pharmaceuticals, Inc. announced.
Frontotemporoparietal transcranial direct current stimulation (tDCS) is an effective and safe add-on treatment for improving negative symptoms in patients with schizophrenia, according to a study published online in JAMA Psychiatry.
Genetic variants associated with left-handedness influence brain connectivity and might be related to the pathogenesis of such neuropsychiatric diseases as Parkinson's disease and schizophrenia, researchers from UK report.
Deficits in amplitude of the auditory P300 event-related potential, a measure that can be detected by EEG, may be a prognostic biomarker of outcomes in patients with psychosis risk syndrome (PRS), researchers say.